JSSH(SZ:000518)2024-07-09 10:29Financial Performance - The company expects a net loss attributable to shareholders of approximately -20 million to -10 million CNY, representing a decrease in loss compared to the same period last year, which was -37.78 million CNY[3] - The expected loss after deducting non-recurring gains and losses is approximately -21 million to -10.5 million CNY, also showing a reduction compared to last year's loss of -37.93 million CNY[3] - The basic earnings per share are estimated to be approximately -0.0194 to -0.0097 CNY, compared to -0.0367 CNY per share in the same period last year[3] Reasons for Loss - The main reason for the loss and reduced loss compared to the previous year is the decline in revenue and sales expenses of the subsidiary Beijing Sihuan Bio-Pharmaceutical Co., Ltd.[4] Forecast and Estimates - The performance forecast data is based on preliminary estimates by the company's finance department, with specific figures to be confirmed in the 2024 semi-annual report[5]